The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Ondansetron Kabi 0.08 mg/ml solution for infusion



Fresenius Kabi Deutschland GmbHPA2059/080/001

Main Information

Trade NameOndansetron Kabi 0.08 mg/ml solution for infusion
Active SubstancesOndansetron hydrochloride dihydrate
Dosage FormSolution for infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/080/001

Group Information

ATC CodeA04AA01 ondansetron

Status

License statusAuthorised
Licence Issued10/06/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back